By Deena Beasley Nov 5 (Reuters) – A trial of Pfizer Inc’s experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday. The results appear to surpass those seen with Merck & Co Inc’s pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious… Source link
Read More »Pfizer says antiviral pill cuts risk of severe COVID-19 by 89% – Yahoo Money
